Leslie Rose, MD
Rheumatology · Denver, CONPI 1871649400
Payments from drug & device makers
Across 583 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$1K
- Pfizer$1K
- UCB, Inc.$995
- AstraZeneca$792
- Inari Medical, Inc.$529
- plus $4K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 168 | $2,666 |
| AbbVie | 56 | $1,101 |
| Pfizer | 74 | $1,033 |
| UCB, Inc. | 49 | $995 |
| AstraZeneca(2 entities) | 36 | $792 |
| Inari Medical, Inc. | 4 | $529 |
| Lilly USA, LLC | 28 | $427 |
| Johnson & Johnson(2 entities) | 22 | $416 |
| Novartis | 23 | $393 |
| GSK | 23 | $376 |
| Genentech USA, Inc. | 26 | $354 |
| Cvrx, Inc. | 2 | $344 |
| E.r. Squibb & Sons, L.L.C. | 9 | $172 |
| Mallinckrodt Enterprises LLC | 9 | $156 |
| Regeneron Healthcare Solutions, Inc. | 7 | $136 |
| Mallinckrodt Hospital Products Inc. | 6 | $130 |
| Radius Health, Inc. | 5 | $118 |
| Boehringer Ingelheim | 3 | $88 |
| Sobi, Inc | 3 | $76 |
| Merck | 4 | $49 |
| Hikma Pharmaceuticals USA | 3 | $48 |
| Bristol Myers Squibb | 2 | $45 |
| Kyowa Kirin, Inc. | 2 | $44 |
| Aurinia Pharma U.S., Inc. | 2 | $44 |
| Organon | 2 | $41 |
| Fresenius Kabi USA, LLC | 2 | $41 |
| Sanofi | 2 | $30 |
| ANI Pharmaceuticals, Inc. | 1 | $29 |
| Mylan Institutional Inc. | 1 | $29 |
| Zimmer Biomet | 1 | $29 |
| Antares Pharma, Inc. | 2 | $28 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Pacira Therapeutics, Inc. | 1 | $21 |
| Sebela Pharmaceuticals Inc. | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Celltrion USA Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$10,872 in reported general payments places this provider in the 70th percentile of 108 rheumatology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Denver
- Christopher AntoliniDenver$6.9M
- Mary DemoruelleDenver$1.2M
- Aryeh FischerDenver$193K
- Adam BerlinbergDenver$94K
- Stuart KassanDenver$75K
- Mehrnaz Maleki FischbachDenver$72K
- Rennie McCabeDenver$58K
- Barbara GoldsteinDenver$47K
- Vance BrayDenver$42K
- Joel HirshDenver$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.